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Abstract
Backgrounds: This study aims to understand the factors that influence whether patients receive potentially
curative treatment for early stage lung cancer. A key question was whether indigenous Māori patients were less
likely to receive treatment.
Methods: Patients included those diagnosed with early stage lung cancer in 2011–2018 and resident in the New
Zealand Midland Cancer Network region. Logistic regression model was used to estimate the odds ratios of having
curative surgery/ treatment. The Kaplan Meier method was used to examine the all-cause survival and Cox proportional
hazard model was used to estimate the hazard ratio of death.
Results: In total 419/583 (71.9%) of patients with Stage I and II disease were treated with curative intent - 272 (46.7%)
patients had curative surgery. Patients not receiving potentially curative treatment were older, were less likely to have
non-small cell lung cancer (NSCLC), had poorer lung function and were more likely to have an ECOG performance
status of 2+. Current smokers were less likely to be treated with surgery and more likely to receive treatment with
radiotherapy and chemotherapy. Those who were treated with surgery had a 2-year survival of 87.8% (95% CI: 83.8–
91.8%) and 5-year survival of 69.6% (95% CI: 63.2–76.0%). Stereotactic ablative body radiotherapy (SABR) has equivalent
effect on survival compared to curative surgery (hazard ratio: 0.77, 95% CI: 0.37–1.61). After adjustment we could find
no difference in treatment and survival between Māori and non-Māori.
Conclusions: The majority of patients with stage I and II lung cancer are managed with potentially curative treatment
– mainly surgery and increasingly with SABR. The outcomes of those being diagnosed with stage I and II disease and
receiving treatment is positive with 70% surviving 5 years.
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Background
Lung cancer is the leading cause of cancer death in New
Zealand [1]. Mortality in Māori, the indigenous people in
New Zealand, is 2.6 times greater than in New Zealand
Europeans [1]. Overall, outcomes from lung cancer in
New Zealand are poor with a 5-year survival of only 11%
[2]. This is mainly because the majority of lung cancer pa-
tients are diagnosed at late stage. In a recent study of lung
cancer patients in our New Zealand region, only 16.5%
were diagnosed with early stage (stage I and II) lung can-
cer [3].
Patients with early stage disease can be considered cur-
able with successful surgery, or stereotactic ablative body
radiotherapy (SABR) [4]. Some stage II and III patients
also have successful outcomes with radical radiotherapy
and chemo radiotherapy. Surgical resection rates for lung
cancer vary between countries and even between centres
in a particular country [5]. Overall, 14.7% of non-small cell
lung cancer (NSCLC) patients receive surgery in New
Zealand compared to 19.1% in Victoria, Australia [6, 7].
Previous studies in New Zealand have reported lower
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surgical rates in Māori [8]. New Zealand is looking to im-
prove the proportion of lung cancer patients diagnosed
with early stage through the use of an educational cam-
paign. However, we have limited data on how early stage
lung cancer is currently managed? There are also limited
data on the outcomes of treatment of early stage disease.
The Midland Lung Cancer Register collects data from
four District Health Boards (DHB) with a combined
population of 800,000 residents. Tertiary lung cancer
management is principally based at Waikato Hospital
[3]. Waikato Hospital provides both surgical services
and radiotherapy services for cancer patients for the re-
gion; with radiotherapy services also available in the Bay
of Plenty DHB. This study aims to understand the fac-
tors that influence whether patients receive potentially
curative treatment for their lung cancer, to understand
which patients receive surgical management, and to
examine the outcomes in those receiving surgery, other
forms of treatment compared to those patients who re-
ceive palliative care.
Methods
We analysed lung cancer data from the Midland Lung
Cancer Register between January 2011 and December
2018 [3]. The Midland Lung Cancer Register is derived
from data collected at multidisciplinary meetings (MDMs)
within the region and complemented by data sourced
from the New Zealand Cancer Registry (NZCR). Patients
diagnosed with stage I and II lung cancer (ICD code: C33,
C34) and resident in the Midland Cancer Network region
(including Waikato, Lakes, Bay of Plenty and Tairawhiti
District Health Board) in 2011–2018 were included. Pa-
tients that were not discussed at an MDM were identified
by the NZCR, and missing data was included from exam-
ination of their clinical records. For those who did not
have a record of treatment, patient notes were searched to
ascertain the reasons for no treatment. These were cate-
gorised into: comorbidities, poor lung function, poor East-
ern Cooperative Oncology Group (ECOG) performance
status (2+) [9], high risk of surgical complications, patient
refusal or unknown reasons.
Data collected on individual patients included age, sex, eth-
nicity, DHB of domicile, type of lung cancer (NSCLC, small
cell, others and unknown), stage of cancer, lung function
(FEV1 measurement), ECOG status, and presence of known
co-morbidities as measured by Charlson Index [10]. We then
identified the treatment received by patients, including cura-
tive surgery (lobectomy, partial resection of lung and pneu-
monectomy), curative radiotherapy (radical radiotherapy),
SABR, curative chemo radiation or palliative treatment which
could include palliative chemo radiation, palliative chemo-
therapy, or symptomatic palliative care only. Mortality data
were derived from the Midland Lung Cancer Register, New
Zealand Cancer Registry and hospital system (iPM) with a
censor date of 25 June 2019. Statistical analyses were then
performed on this Combined Lung Cancer Register.
In order to determine if there is an ethnic basis to in-
equity of care, patient demographics, tumour character-
istics and treatment were compared between Māori and
non-Māori patients. The difference was examined with
Chi-square test. Reasons for not having potentially cura-
tive surgery as the primary treatment were also explored
and classified into comorbidity, lung function problems,
poor ECOG status, surgical complications, patient re-
fusal and unknown/other reasons. Logistic regression
model was used to estimate the odds ratios of having
curative treatment for Māori patients compared with
non-Māori patients after adjustment for patient demo-
graphics and tumour characteristics. We also examined
the factors that influence whether patients received al-
ternative curative treatment compared to surgery.
The Kaplan Meier method was used to examine the
all-cause survival by treatment option and by ethnicity
(Māori vs non-Māori). For survival analyses, patients
without mortality information were considered to be
censored on 25 June 2019. Cox proportional hazard
model was used to estimate the hazard ratio of death for
Māori compared to non-Māori after adjustment for age,
sex, year of diagnosis, stage, comorbidities and treat-
ments. All data analyses were performed in IBM SPSS
statistics 25 (New York, United States).
Results
The Combined Lung Cancer Register included 3331
resident cases (1050 Māori and 2281 non-Māori) be-
tween 2011 and 2018. This study included 583/3331
(17.5%) with early stage disease (Table 1). This was made
up of 169/1050 (16.1%) Māori and 414/2281 (18.1%)
non-Māori patients. Over 90% of the early stage patients
were either a current smoker (30.9%) or ex-smoker
(60.1%). Among the lung cancer patients, 47.7% had a
history of chronic obstructive pulmonary disease
(COPD). There were 452 cases of NSCLC, 14 cases of
small cell lung cancer, and 106 patients did not have a
pathology report. A record of unknown pathology was
associated with significant comorbidities in 37 (34.9%)
patients, frailty/high risk – ECOG 2+ 10 (9.4%) and very
poor lung function 25 (23.6%). The 169 Māori patients
were younger, more likely to be current smokers, have a
diagnosis of COPD and have NSCLC-other and small
cell lung cancer, and more likely to have FEV1 of < 50%
than non-Māori patients.
In total 419/583 (71.9%) of patients with Stage I and II
disease were treated with curative intent - 272 (46.7%) pa-
tients had curative surgery, including 199 lobectomies, 59
partial resection of lung, and 14 pneumonectomy
(Table 2). Another 64 (11.0%) patients were treated with
SABR, 67 (11.5%) received curative radical radiotherapy,
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and 16 (2.7%) had curative chemo/radiotherapy. Amongst
those not having curative treatment (164 (28.1%)), 33
(5.7%) had palliative radiotherapy, 14 (2.4%) had palliative
chemotherapy, and 117 (20.1%) had best supportive care
alone. Māori patients appeared to be less likely to have
curative surgery (39.6% vs 49.5%, p-value = 0.027), but
were as likely to have curative treatment as non-Māori pa-
tients (70.4% vs 72.5%, p-value = 0.618). The principal rea-
son recorded in the patient records indicating why these
lung cancer patients did not have curative treatment
Table 1 Patient demographics and tumour characteristics
Subgroup Māori Non-Māori P-value (Chi-square test) Total
Sex
Female 104 (61.5%) 220 (53.1%) 0.064 324 (55.6%)
Male 65 (38.5%) 194 (46.9%) 259 (44.4%)
Age (years)
< 60 35 (20.7%) 53 (12.8%) < 0.001 88 (15.1%)
60–69 65 (38.5%) 120 (29.0%) 185 (31.7%)
70–79 57 (33.7%) 170 (41.1%) 227 (38.9%)
80+ 12 (7.1%) 71 (17.1%) 83 (14.2%)
Smoking status
Current smoker 63 (40.4%) 104 (27.0%) < 0.001 167 (30.9%)
Ex-smoker 91 (58.3%) 234 (60.8%) 325 (60.1%)
Never smoked 2 (1.3%) 47 (12.2%) 49 (9.1%)
Unknown 13 29 42
Charlson Comorbidity
0 37 (21.9%) 119 (28.7%) < 0.001 156 (26.8%)
1 44 (26.0%) 147 (35.5%) 191 (32.8%)
2 51 (30.2%) 99 (23.9%) 150 (25.7%)
3 29 (17.2%) 33 (8.0%) 62 (10.6%)
4+ 8 (4.7%) 16 (3.9%) 24 (4.1%)
COPD
No 57 (39.9%) 207 (57.2%) < 0.001 264 (52.3%)
Yes 86 (60.1%) 155 (42.8%) 241 (47.7%)
Unknown 26 52 78
Cell type
NSCLC 124 (91.2%) 328 (96.2%) < 0.001 452 (94.8%)
Others 2 (1.5%) 9 (2.6%) 11 (2.3%)
Small cell 10 (7.4%) 4 (1.2%) 14 (2.9%)
Unknown 33 73 106
FEV1
< 50% 46 (30.3%) 63 (17.4%) < 0.001 109 (21.2%)
50%~ 80% 70 (46.1%) 139 (38.4%) 209 (40.7%)
80%+ 36 (23.7%) 160 (44.2%) 196 (38.1%)
Unknown 17 52 69
ECOG
0 51 (32.3%) 157 (40.6%) 0.194 208 (38.2%)
1 73 (46.2%) 158 (40.8%) 231 (42.4%)
2+ 34 (21.5%) 72 (18.6%) 106 (19.4%)
Unknown 11 27 38
Total 169 414 583
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included significant comorbidities in 37 (22.6%) patients,
24 (14.6%) poor lung function, 24 (14.6%) poor ECOG sta-
tus, 19 (11.6%) high risk of surgical complications, 16
(9.8%) patient refusal and 43 (26.2%) unrecorded.
The logistic regression model showed that age, year of
diagnosis, cancer stage, cancer cell type, FEV1 and ECOG
status had an impact on the likelihood of having curative
treatment (Table 3). Patients who were younger, were di-
agnosed in more recent years, had stage I disease, had
NSCLC, had FEV1 of 80%+, and had an ECOG score of 0
were more likely to receive curative treatment. Amongst
those who received curative treatments, younger patients
were more likely to have surgery as the primary treatment
(odds ratio: 0.91, 95%:0.87–0.95). Current smokers and
ex-smokers were less likely to have surgery and more
likely to be treated with radiotherapy and chemotherapy
than people who never smoked (respective odds ratio:
0.11 (95% Confidence interval (CI): 0.02–0.46); 0.23 (95%
CI: 0.06–0.89)). Patients who had NSCLC, had FEV1 of
80%+, and had an ECOG score of 0 were more likely to
undergo surgery. After adjustment for other factors we
did not find a difference in access to curative treatment
and curative surgery between Māori and non-Māori pa-
tients (respective odds ratio: 0.80 (95% CI: 0.46–1.38); 1.03
(95% CI: 0.53–2.00)).
There were 217 deaths (37.3%) in this cohort with a
median follow-up time of 27 months and a mean follow-
up time 34 months. Outcomes in patients with stage I
and II lung cancer varied depending on the treatment
received (Fig. 1). Those who were treated with surgery
had a 2-year survival of 87.8% (95% CI: 83.8–91.8%) and
5-year survival of 69.6% (95% CI: 63.2–76.0%). SABR has
only been available in the region since mid 2015 but out-
comes are similar to surgery in the first 2 years post
treatment (2-year survival: 85.2, 95% CI: 75.8–94.7%,
log-rank test p-value = 0.556). Prior to the use of SABR,
some patients were offered radiotherapy with curative
intent and in this group of patients 2-year survival is
only 65.3% (95% CI: 53.1–77.4%) and 5-year survival was
50%. Patients offered palliative treatment only had a 2-
year survival of 45.0% (95% CI: 37.0–53.0%) and 5-year
survival of 31.8% (95% CI: 23.9–39.6%).
Māori patients had a similar survival to non-Māori pa-
tients (Fig. 2, Log-rank test p-value = 0.091). The 2-year
and 5-year survival for Māori patients was 69.4% (95%
CI: 62.2–76.7%) and 47.1% (95% CI: 37.8–56.4%), com-
pared to 73.5% (95% CI: 69.1–77.9%) and 59.3% (95% CI:
53.9–64.8%) for non-Māori patients.
The hazard ratio (Table 4) of all-cause mortality for
Māori patients compared to non-Māori patients was 1.25
(95% CI: 0.92–1.69, p-value = 0.150). SABR has equivalent
effect on survival compared to curative surgery (hazard ra-
tio: 0.77, 95% CI: 0.37–1.61). The all-cause survival for
stage I and II lung cancer patients has improved over time
(hazard ratio: 0.94, 95% CI: 0.87–1.00).
Discussion
We found that 71.9% of early stage lung cancer patients
in our region were treated with potentially curative
treatment. The commonest form of treatment was sur-
gery. Thus in the Midlands Region a total of 272/3331
(8.2%) of lung cancer patients were treated with curative
surgery. This low rate of surgical treatment is similar to
that found in the UK but lower than the rate reported in
Australia and some European countries [11, 12]. While
the advent of SABR has coincided with an increasing
proportion of early stage patients being offered curative
treatment, significant improvement will only be achieved
when the proportion of patients with early stage disease
at diagnosis is increased. This can either be achieved
through greater awareness of symptoms of lung cancer
e.g. through social media campaign [13] and through the
introduction of lung cancer screening [14, 15].
We have shown that there are a number of reasons
why patients do not receive curative treatment. Overall,
less than half of patients with stage I and II disease in
our region 272/583 (46.7%) were treated with surgery.
This figure has not improved from the findings in a
similar New Zealand study in 2004 which reported a
surgery rate of 56% of stage I and II NSCLC [7]. Another
147/583 (25.2%) of patients in our study were treated
with alternative potentially curative treatment while 164/
583 (28.1%) were treated with palliative care only. Pa-
tients with stage I and II NSCLC receiving palliative care
were older than those who had curative treatment (mean
age of 73 years vs 68 years). Other reasons included can-
cer stage –(stage II cases were less likely to be treated
curatively than stage I), cancer cell type (small cell tu-
mours were less likely to be treated than NSCLC), and
those with COPD or poor respiratory function who were
less likely to receive surgery or curative treatment as
were those with a poor ECOG status. These findings are
Table 2 Primary treatment for lung cancer patients by ethnicity
Primary treatment Māori Non-Māori Total
Curative surgery 67 (39.6%) 205 (49.5%) 272 (46.7%)
Lobectomy 49 (29.0%) 150 (36.2%) 199 (34.1%)
Partial resection of lung 16 (9.5%) 43 (10.4%) 59 (10.1%)
Pneumonectomy 2 (1.2%) 12 (2.9%) 14 (2.4%)
SABR 22 (13.0%) 42 (10.1%) 64 (11.0%)
Radical radiotherapy 23 (13.6%) 44 (10.6%) 67 (11.5%)
Curative chemo/radiotherapy 7 (4.1%) 9 (2.2%) 16 (2.7%)
Palliative radiotherapy 14 (8.3%) 19 (4.6%) 33 (5.7%)
Palliative chemotherapy 4 (2.4%) 10 (2.4%) 14 (2.4%)
Supportive care 32 (18.9%) 85 (20.5%) 117 (20.1%)
Total 169 414 583
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similar to the findings from a Danish study [16] of stage
I lung cancer and the historical New Zealand study [7].
SCLC proliferates more rapidly and has a high propen-
sity to metastasise. Most cases will present with locally ad-
vanced or metastatic disease. On rare occasions, patients
are identified with small cell lung cancer (SCLC) histology
but with early stage disease potentially suitable for resec-
tion [17]. Overall our cohort had 440/3331 (13%) small
cell lung cancers. There were only 14 small cell lung can-
cer cases in our group of stage I and II diseases, and only
one had curative surgery. In a large cohort of 45,848 pa-
tients with SCLC only 1% were treated surgically [18]. The
5-year survival in this cohort from the turn of the century
was only 31% and the HR compared with NSCLC was
1.47 [18]. Our findings suggest that surgical intervention
for SCLC is a rare event, partly because few cases present
with early stage disease and other treatment modalities
are more likely to be taken up.
Our study also shows that patients who identify as
Māori are less likely to receive curative surgical resection
of stage I and II lung cancer than those who do not iden-
tify as Māori. This finding was based on the unadjusted
analysis, and the difference disappeared after adjustment
for other factors. This could suggest that the New Zealand
Table 3 Adjusted odds ratios from logistic regression model
Subgroup Having curative treatment vs no curative treatment Having surgery vs other curative treatment
Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Sex
Female Ref Ref
Male 0.85 (0.51 - 1.41) 0.536 1.26 (0.70 - 2.29) 0.446
Ethnicity
Māori 0.80 (0.46 - 1.38) 0.424 1.03 (0.53 - 2.00) 0.932
Non-Māori Ref Ref
Age (Continuous) 0.92 (0.89 - 0.95) < 0.001 0.91 (0.87 - 0.95) < 0.001
Smoking status
Current smoker 0.40 (0.12 - 1.38) 0.149 0.11 (0.02 - 0.46) 0.003
Ex-smoker 0.49 (0.15 - 1.57) 0.229 0.23 (0.06 - 0.89) 0.033
Never smoked Ref Ref
Charlson Comorbidity
0 Ref Ref
1 0.82 (0.36 - 1.87) 0.644 0.43 (0.17 - 1.11) 0.080
2 1.06 (0.45 - 2.50) 0.902 0.35 (0.13 - 0.93) 0.035
3 0.93 (0.34 - 2.54) 0.894 0.20 (0.06 - 0.73) 0.015
4+ 0.55 (0.15 - 2.02) 0.365 0.10 (0.02 - 0.56) 0.009
Year of diagnosis (Continuous) 1.15 (1.03 - 1.28) 0.015 0.75 (0.65 - 0.86) < 0.001
Stage
I Ref Ref
II 0.29 (0.17 - 0.48) < 0.001 0.58 (0.31 - 1.08) 0.088
Cell type
NSCLC Ref Ref
Others 0.29 (0.17 - 0.51) < 0.001 0.08 (0.03 - 0.23) < 0.001
FEV1
< 50% 0.35 (0.16 - 0.77) 0.009 0.04 (0.01 - 0.12) < 0.001
50%~ 80% 0.70 (0.36 -\ 1.38) 0.304 0.42 (0.20 - 0.85) 0.016
80%+ Ref Ref
ECOG
0 Ref Ref
1 0.52 (0.26 - 1.02) 0.056 0.57 (0.30 - 1.09) 0.091
2+ 0.13 (0.06 - 0.26) < 0.001 0.14 (0.05 - 0.40) < 0.001
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Fig. 1 All-cause survival by treatment option
Fig. 2 All-cause survival between Māori and non-Māori
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healthcare system is ensuring equity of access to curative
surgical resection for patients. Māori presenting with early
stage disease are younger than non-Māori, and more likely
to have COPD, be a current smoker, have an FEV1 less
than 50% and have small cell histology. Māori generally
have lower socioeconomic status which is associated with
poor surviva [19, 20]. After adjustment for these factors it
appears that Māori are not less likely to receive curative
treatment (odds ratio 0.80, 95% CI 0.46–1.38) or surgery
(odds ratio 1.03, 95% CI: 0.53–2.00). It maybe this finding
is a Type 2 error and if we had a bigger sample then po-
tentially we might show a difference. This means that we
need to continue to monitor access to curative treatments
for Māori if we are to reduce the inequities in outcomes
that we know are present [7, 21].
Our findings show that the all-cause survival from sur-
gery in this group of patients are 85% at 2 years and 70%
at 5 years. This is similar to the survival reported in a
2004 study where the 2-year survival was 81% [7]. This
supports the assertion that early stage lung cancer can
be “cured” [22]. Indeed if we look just at the 199 NSCLC
patients treated with lobectomy we find the 5-year sur-
vival is over 70% which is comparable with the findings
from studies in major centres in the USA [22].
Patients with stage I and II NSCLC treated with SABR
have comparable outcomes to those treated with sur-
gery. This is despite the finding that those treated with
curative intent with SABR tended to have additional risk
factors including older age, higher ECOG status score,
more comorbidities and more smokers. The numbers of
patients treated with SABR is relatively small and further
follow up of a greater number of patients is needed to
confirm this finding but the initial results are very en-
couraging. A systematic review [23] reported that the
overall and cancer-specific survival between SABR and
lobectomy for stage I NSCLC were similar after 1-year
follow-up, but lobectomy appeared to have more
favourable outcomes after 3-year and 5-year follow-up.
However, this systematic review only included one ran-
domised clinical trial [24] and the other six included
studies were cohort studies which may have been subject
to bias [25–30].
Outcomes in patients managed with palliative care are
relatively poor where only 30% of palliative patients with
Stage I and II disease are surviving 5 years. Many of
these patients are older and have significant comorbidi-
ties which impact on overall survival. The small number
of patients offered palliative chemotherapy appear to be
doing better with a 2-year survival of 60%. However,
overall survival in this group of patients managed with
supportive/palliative care is higher than previous reports.
Stevens et al. [7] only showed 20% survival with 2 years
follow-up, while our study has shown similar improve-
ment year by year during the study period.
One of the strengths of our study is that it was based
on the comprehensive lung cancer register, with rela-
tively complete data on patient demographics, tumour
characteristics and treatment. The limitations of this
study included the small number of patients and short
follow-up time in some treatment group, e.g. SABR. Also
as an observation study, this study is prone to selection
bias.
Conclusions
The majority of patients with stage I and II lung cancer
are managed with potential curative treatment – mainly
surgery and increasingly SABR. After adjustment for key
variables such as smoking, comorbidities and lung func-
tion status, the likelihood of Māori patients having
Table 4 Adjusted hazard ratio for overall survival from Cox
proportional hazard model
Factors Hazard
ratio
95% CI of hazard
ratio
P-value
Sex
Female Ref
Male 1.21 (0.91 - 1.62) 0.195
Ethnicity
Māori 1.25 (0.92 - 1.69) 0.151
Non-Māori Ref
Age (Continuous) 1.01 (0.99 - 1.03) 0.172
Charlson Comorbidity
0 Ref
1 1.10 (0.70 - 1.75) 0.673
2 1.07 (0.66 - 1.73) 0.794
3 1.02 (0.55 - 1.86) 0.959
4+ 1.19 (0.58 - 2.44) 0.640
Smoking status
Current smoker 2.51 (1.06 - 5.94) 0.037
Ex-smoker 2.24 (0.96 - 5.22) 0.061
Never smoked Ref
Year of diagnosis (Continuous) 0.94 (0.87 - 1.00) 0.068
Stage
I Ref
II 1.35 (1.02 - 1.80) 0.039
Primary treatment
Curative surgery Ref
SABR 0.77 (0.37 - 1.61) 0.486
Radiotherapy 1.94 (1.23 - 3.07) 0.005
Curative chemo/Rad 1.80 (0.80 - 4.03) 0.153
Palliative rad 2.89 (1.72 - 4.85) < 0.001
Palliative chemo 1.69 (0.66 - 4.32) 0.270
Supportive care 3.35 (2.26 - 4.96) < 0.001
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curative treatment was similar to non-Māori. This sug-
gest that outcomes for Māori patients can be improved
by addressing smoking and the management of comor-
bidities. While the outcomes of those being diagnosed
with stage I and II disease and receiving treatment is
positive with 70% surviving 5 years, the next target is to
substantially increase the population of lung cancer pa-
tients diagnosed with early stage disease.
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